Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
reported financial results and business highlights for the fourth
quarter and year ended December 31, 2021, and provided full-year
2022 financial guidance.
Fourth Quarter 2021 Financial Highlights
- Total net revenue of $47.6 million, compared to $45.2 million
in the fourth quarter of 2020
- MACI® net revenue of $37.3 million, Epicel® net revenue of $9.7
million, and NexoBrid® revenue of $0.5 million related to the U.S.
Biomedical Advanced Research and Development Authority (BARDA)
procurement for emergency response preparedness
- Gross margin of 72%, compared to 74% in the fourth quarter of
2020
- Net income of $4.5 million, or $0.09 per share, compared to
$12.2 million, or $0.25 per share, in the fourth quarter of
2020
- Non-GAAP adjusted EBITDA of $12.8 million, compared to $16.0
million in the fourth quarter of 2020
- Operating cash flow of $10.6 million
Full Year 2021 Financial Highlights
- Total net revenue of $156.2 million, compared to $124.2 million
in 2020
- MACI net revenue of $111.6 million, Epicel net revenue of $41.5
million, and NexoBrid revenue of $3.1 million related to BARDA
procurement for emergency response preparedness
- Gross margin of 68%, compared to gross margin of 68% in
2020
- Net loss of $7.5 million, or $0.16 per share, compared to net
income of $2.9 million, or $0.06 per share, in 2020
- Non-GAAP adjusted EBITDA of $29.5 million, compared to $18.6
million in 2020
- Operating cash flow of $29.0 million
- As of December 31, 2021, the Company had approximately $129
million in cash and investments, compared to $100 million as of
December 31, 2020, and no debt
Business Highlights and Updates
- Total net revenue growth of 26% for 2021, in line with the
Company’s compounded annual revenue growth rate since the launch of
MACI in 2017
- Full-year net revenue growth of 18% for MACI, achieving record
quarterly revenue in the fourth quarter
- Full-year net revenue growth of 51% for Epicel and the fifth
straight quarter with revenue over $9.5 million
- Achieved 20% growth in surgeons taking MACI biopsies and 30%
growth in MACI biopsies for the year, with a record quarterly high
in the number of biopsies and the number of surgeons taking
biopsies in the fourth quarter
- Achieved over 30% growth in Epicel biopsies and burn centers
treating patients with Epicel compared to 2020
- Announced plans for a new
state-of-the-art cell therapy manufacturing facility and corporate
headquarters to support long-term growth
“We delivered another strong year of revenue growth and
generated record adjusted EBITDA and operating cash flow to end the
year in a very strong financial position,” said Nick Colangelo,
President and CEO of Vericel. “The Company continues to execute
very well across all areas of the business, generating record
revenue and biopsies for MACI in the fourth quarter and driving
over 50% growth in Epicel revenue for the year. Looking forward,
given the significant market opportunities and the continued
progress across both of our franchises, we believe that we are
well-positioned for continued strong revenue and profitability
growth in 2022 and the years ahead.”
2022 Financial Guidance
- Total net revenue for 2022 expected
to be in the range of $178 to $189 million
- MACI revenue expected to be in the
range of $132 to $141 million
- Epicel revenue expected to be in the
range of $45.5 to $47.5 million
- Gross margin expected to be
approximately 70%
- Adjusted EBITDA margin expected to
be approximately 21%
Fourth Quarter 2021 ResultsTotal net revenue
for the quarter ended December 31, 2021 increased 5% to $47.6
million, compared to $45.2 million in the fourth quarter of 2020.
Total net product revenue for the quarter included $37.3 million of
MACI (autologous cultured chondrocytes on porcine collagen
membrane) net revenue and $9.7 million of Epicel (cultured
epidermal autografts) net revenue, compared to $34.7 million of
MACI net revenue and $9.6 million of Epicel net revenue,
respectively, in the fourth quarter of 2020. Total net revenue for
the quarter also included $0.5 million of revenue related to the
procurement of NexoBrid (concentrate of proteolytic enzymes
enriched in bromelain) by BARDA for emergency response
preparedness, compared to $1.0 million in the fourth quarter of
2020.
Gross profit for the quarter ended December 31, 2021 was $34.0
million, or 72% of net revenue, compared to $33.6 million, or 74%
of net revenue, for the fourth quarter of 2020.
Total operating expenses for the quarter ended December 31, 2021
were $29.9 million, compared to $21.4 million for the same period
in 2020. The increase in operating expenses was primarily due to an
increase in stock-based compensation expense driven by share price
appreciation.
Net income for the quarter ended December 31, 2021 was $4.5
million, or $0.09 per share, compared to net income of $12.2
million, or $0.25 per share, for the fourth quarter of 2020.
Non-GAAP adjusted EBITDA for the quarter ended December 31, 2021
was $12.8 million, or 27% of net revenue, compared to $16.0
million, or 35% of net revenue, for the fourth quarter of 2020. A
table reconciling non-GAAP measures is included in this press
release for reference.
Full-Year 2021 ResultsTotal net revenue for the
year ended December 31, 2021 increased 26% to $156.2 million,
compared to $124.2 million in 2020. Total net product revenue for
the year included $111.6 million of MACI net revenue and $41.5
million of Epicel net revenue, compared to $94.4 million of MACI
net revenue and $27.5 million of Epicel net revenue, respectively,
in 2020. Total net revenue in 2021 also included $3.1 million of
revenue related to the procurement of NexoBrid by BARDA for
emergency response preparedness, compared to $2.2 million of
revenue in 2020.
Gross profit for the year ended December 31, 2021 was $106.0
million, or 68% of net revenue, compared to $84.2 million, or 68%
of net revenue, in 2020.
Total operating expenses for the year ended December 31, 2021
were $113.9 million, compared to $81.9 million in 2020. The
increase in operating expenses was primarily due to an increase in
stock-based compensation expense driven by share price appreciation
and lower spend in 2020 due to COVID-19-related factors.
Net loss for the year ended December 31, 2021 was $7.5 million,
or $0.16 per share, compared to net income of $2.9 million, or
$0.06 per share, in 2020.
Non-GAAP adjusted EBITDA for the year ended December 31, 2021
was $29.5 million, or 19% of net revenue, compared to $18.6
million, or 15% of net revenue, in 2020. A table reconciling
non-GAAP measures is included in this press release for
reference.
As of December 31, 2021, the Company had approximately $129
million in cash and investments, compared to approximately $100
million as of December 31, 2020, and no debt.
Conference Call Information Today’s conference
call will be available live at 8:30am Eastern Time and can be
accessed through the Investor Relations section of the Vericel
website at http://investors.vcel.com/events-presentations. A slide
presentation with highlights from today’s conference call will be
available on the webcast and in the Investor Relations section of
the Vericel website. Please access the site at least 15 minutes
prior to the scheduled start time in order to download the required
audio software, if necessary. To participate in the live call by
telephone, please call (877) 312-5881 and reference Vericel
Corporation’s fourth quarter 2021 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until February 24, 2023. A replay of the call will also be
available until 11:30am (EDT) on February 28, 2022 by calling (855)
859-2056, or from outside the U.S. by calling (404) 537-3406. The
conference ID is 5795764.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The Company markets two cell therapy products in the
United States. MACI (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with
deep-dermal or full-thickness burns greater than or equal to 30% of
total body surface area. The Company also holds an exclusive
license for North American rights to NexoBrid, a registration-stage
biological orphan product for debridement of severe thermal
burns. For more information, please visit the Company’s
website at www.vcel.com.
GAAP v. Non-GAAP MeasuresVericel’s reported
earnings are prepared in accordance with generally accepted
accounting principles in the United States, or GAAP, and represent
earnings as reported to the Securities and Exchange Commission.
Vericel has provided in this release certain financial
information that has not been prepared in accordance with
GAAP. Vericel’s management believes that the non-GAAP
adjusted EBITDA described in the release, which includes
adjustments for specific items that are generally not indicative of
our core operations, provides additional information that is useful
to investors in understanding Vericel’s underlying performance,
business and performance trends, and helps facilitate
period-to-period comparisons and comparisons of its financial
measures with other companies in Vericel’s industry. However,
the non-GAAP financial measures that Vericel uses may differ from
measures that other companies may use. Non-GAAP financial
measures are not required to be uniformly applied, are not audited
and should not be considered in isolation or as substitutes for
results prepared in accordance with GAAP.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
(MediWound) and is used under license to Vericel Corporation. ©
2022 Vericel Corporation. All rights reserved.
Forward-Looking StatementsVericel cautions you
that all statements other than statements of historical fact
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements. Although we
believe that we have a reasonable basis for the forward-looking
statements contained herein, they are based on current expectations
about future events affecting us and are subject to risks,
assumptions, uncertainties and factors relating to our operations
and business environment, all of which are difficult to predict and
many of which are beyond our control. Our actual results may differ
materially from those expressed or implied by the forward-looking
statements in this press release. These statements are often, but
are not always, made through the use of words or phrases such as
“anticipates,” “intends,” “estimates,” “plans,” “expects,”
“continues,” “believe,” “guidance,” “outlook,” “target,” “future,”
“potential,” “goals” and similar words or phrases, or future or
conditional verbs such as “will,” “would,” “should,” “could,”
“may,” or similar expressions.
Among the factors that could cause actual results to differ
materially from those set forth in the forward-looking statements
include, but are not limited to, uncertainties associated with our
expectations regarding future revenue, growth in revenue, market
penetration for MACI and Epicel, growth in profit, gross margins
and operating margins, the ability to achieve or sustain
profitability, contributions to adjusted EBITDA, the expected
target surgeon audience, potential fluctuations in sales and
volumes and our results of operations over the course of the year,
timing and conduct of clinical trial and product development
activities, timing of the resubmission to the Food & Drug
Administration (FDA) of a Biologics License Application (BLA) for
NexoBrid seeking approval for the treatment of severe burns in the
United States following MediWound’s receipt of a complete response
letter on June 28, 2021, timing or likelihood of approval by the
FDA of the NexoBrid BLA resubmission, the estimate of the
commercial growth potential of our products and product candidates,
availability of funding from BARDA under its agreement with
MediWound for use in connection with NexoBrid development
activities, competitive developments, changes in third-party
coverage and reimbursement, our ability to supply or meet customer
demand for our products, and the ongoing impacts of the COVID-19
pandemic on our business or the economy generally.
With respect to COVID-19, we are currently unable to predict
whether the recent spread of the COVID-19 Delta and Omicron
variants or a future resurgence of COVID-19 infections that may
limit the effectiveness of approved vaccines will result in future
restrictions on the performance of elective surgical procedures or
affect the availability of physicians and/or their treatment
prioritizations, cause healthcare facility staffing shortages,
effect the willingness or ability of patients to seek treatment, or
heighten the impact of the outbreak on the overall healthcare
infrastructure. Other disruptions or potential disruptions include
restrictions on the ability of Company personnel to travel and
access customers for training, promotion and case support, delays
in product development efforts, and additional government-imposed
quarantines and requirements to “shelter at home” or other
incremental mitigation efforts or initiatives that may impact our
ability to source supplies for our operations or our ability or
capacity to manufacture, sell and support the use of our products.
With respect to NexoBrid, the COVID-19 pandemic may impact the
FDA’s response times to future regulatory submissions, its ability
to monitor our clinical trials, and/or conduct necessary reviews or
inspections of manufacturing facilities involved in the production
of NexoBrid, any or all of which may result in timelines being
materially delayed, which could affect the development and ultimate
commercialization of NexoBrid. The total impact of these
disruptions could have a material impact on the Company’s financial
condition, cash flows and results of operations.
These and other significant factors are discussed in greater
detail in Vericel’s Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the Securities and Exchange
Commission (SEC) on February 24, 2022, and in other filings with
the SEC. These forward-looking statements reflect our
views as of the date hereof and Vericel does not assume and
specifically disclaims any obligation to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
Investor Contact: Eric Burnsir@vcel.com+1 (734)
418-4411
VERICEL
CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS(Unaudited, amounts in thousands, except
per share amounts)
|
|
Three Months Ended December 31, 2021 |
|
Twelve Months Ended December 31, 2021 |
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Product sales, net |
|
47,050 |
|
|
44,256 |
|
|
153,075 |
|
|
121,968 |
|
Other revenue |
|
541 |
|
|
973 |
|
|
3,109 |
|
|
2,211 |
|
Total revenue |
|
47,591 |
|
|
45,229 |
|
|
156,184 |
|
|
124,179 |
|
Cost of product sales |
|
13,559 |
|
|
11,582 |
|
|
50,159 |
|
|
39,951 |
|
Gross profit |
|
34,032 |
|
|
33,647 |
|
|
106,025 |
|
|
84,228 |
|
Research and development |
|
3,924 |
|
|
3,118 |
|
|
16,287 |
|
|
13,020 |
|
Selling, general and administrative |
|
25,967 |
|
|
18,240 |
|
|
97,592 |
|
|
68,836 |
|
Total operating expenses |
|
29,891 |
|
|
21,358 |
|
|
113,879 |
|
|
81,856 |
|
Income (loss) from
operations |
|
4,141 |
|
|
12,289 |
|
|
(7,854 |
) |
|
2,372 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
61 |
|
|
117 |
|
|
224 |
|
|
691 |
|
Interest expense |
|
(1 |
) |
|
(1 |
) |
|
(4 |
) |
|
(6 |
) |
Other income (expense) |
|
8 |
|
|
(5 |
) |
|
52 |
|
|
(13 |
) |
Total other income (expense) |
|
68 |
|
|
111 |
|
|
272 |
|
|
672 |
|
Income (loss) before income
taxes |
|
4,209 |
|
|
12,400 |
|
|
(7,582 |
) |
|
3,044 |
|
Income tax (benefit) expense |
|
(326 |
) |
|
180 |
|
|
(111 |
) |
|
180 |
|
Net income (loss) |
|
4,535 |
|
|
12,220 |
|
|
(7,471 |
) |
|
2,864 |
|
Net income (loss) per common
share: |
|
|
|
|
|
|
|
|
Basic |
|
0.10 |
|
|
0.27 |
|
|
(0.16 |
) |
|
0.06 |
|
Diluted |
|
0.09 |
|
|
0.25 |
|
|
(0.16 |
) |
|
0.06 |
|
Weighted-average common shares
outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
46,821 |
|
|
45,545 |
|
|
46,472 |
|
|
45,221 |
|
Diluted |
|
49,939 |
|
|
48,101 |
|
|
46,472 |
|
|
47,282 |
|
RECONCILIATION OF REPORTED NET INCOME (LOSS)
(GAAP)TO ADJUSTED EBITDA (NON-GAAP MEASURE) -
UNAUDITED |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
(In thousands) |
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Net income (loss) |
|
$ |
4,535 |
|
|
$ |
12,220 |
|
|
$ |
(7,471 |
) |
|
$ |
2,864 |
|
Stock-based compensation expense |
|
|
7,841 |
|
|
|
3,024 |
|
|
|
34,322 |
|
|
|
13,843 |
|
Depreciation and amortization |
|
|
780 |
|
|
|
734 |
|
|
|
2,965 |
|
|
|
2,383 |
|
Net interest income |
|
|
(60 |
) |
|
|
(116 |
) |
|
|
(220 |
) |
|
|
(685 |
) |
Income tax (benefit) expense |
|
|
(326 |
) |
|
|
180 |
|
|
|
(111 |
) |
|
|
180 |
|
Adjusted EBITDA
(Non-GAAP) |
|
$ |
12,770 |
|
|
$ |
16,042 |
|
|
$ |
29,485 |
|
|
$ |
18,585 |
|
VERICEL
CORPORATIONCONDENSED CONSOLIDATED BALANCE
SHEETS(Unaudited, amounts in
thousands)
|
|
December 31, |
|
|
|
2021 |
|
|
2020 |
ASSETS |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
|
$ |
68,330 |
|
$ |
33,620 |
Short-term investments |
|
|
35,068 |
|
|
42,187 |
Accounts receivable (net of allowance for doubtful accounts of $40
and $143, respectively) |
|
|
37,437 |
|
|
34,504 |
Inventory |
|
|
13,381 |
|
|
9,356 |
Other current assets |
|
|
4,246 |
|
|
3,893 |
Total current assets |
|
|
158,462 |
|
|
123,560 |
Property and equipment, net |
|
|
13,308 |
|
|
7,633 |
Restricted cash |
|
|
211 |
|
|
211 |
Right-of-use assets |
|
|
45,720 |
|
|
50,105 |
Long-term investments |
|
|
25,687 |
|
|
24,099 |
Other long-term assets |
|
|
317 |
|
|
— |
Total assets |
|
$ |
243,705 |
|
$ |
205,608 |
LIABILITIES AND
SHAREHOLDERS’ EQUITY |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
|
$ |
9,016 |
|
$ |
6,755 |
Accrued expenses |
|
|
14,045 |
|
|
11,293 |
Current portion of operating lease liabilities |
|
|
2,950 |
|
|
4,394 |
Other current liabilities |
|
|
41 |
|
|
41 |
Total current liabilities |
|
|
26,052 |
|
|
22,483 |
Operating lease liabilities |
|
|
47,147 |
|
|
48,789 |
Other long-term liabilities |
|
|
44 |
|
|
76 |
Total liabilities |
|
|
73,243 |
|
|
71,348 |
Total shareholders’ equity |
|
|
170,462 |
|
|
134,260 |
Total liabilities and shareholders’ equity |
|
$ |
243,705 |
|
$ |
205,608 |
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024